Anti-oncolytic virus antigen antibodies and methods of use thereof
Antibodies that specifically bind to a vaccinia virus (VV) A56 or B5 antigen are provided. Fusion proteins and conjugates comprising the antibodies are also provided. Pharmaceutical compositions and kits comprising the antibodies, fusion proteins and conjugates are also provided. Aspects of the disc...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | chi ; eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | BERNARD, FRANU OIS CUMMINGS EMMA J ROUSSEAU JULIE MARIE LIN GUOXIAN BERGQVIST JAN PETER THUMASI-BOATENG KWAME GUO YINYU EUNICE NELSON BRAD SMACINSKI, JULIAN |
| description | Antibodies that specifically bind to a vaccinia virus (VV) A56 or B5 antigen are provided. Fusion proteins and conjugates comprising the antibodies are also provided. Pharmaceutical compositions and kits comprising the antibodies, fusion proteins and conjugates are also provided. Aspects of the disclosure further include methods of using the antibodies, fusion proteins, and conjugates, for example, for therapeutic purposes. In certain embodiments, methods are provided comprising administering to an individual having cancer an antibody, fusion protein or conjugate of the present disclosure wherein the individual comprises cancer cells infected with VV, such as cancer cells infected with VV. And wherein the antibody, fusion protein or conjugate is targeted to a VV antigen infected cancer cell expressed on the surface of the infected cancer cell. Aspects of the disclosure further include methods of targeting an antibody, fusion protein or conjugate that specifically binds to an oncolytic virus (OV) antigen to ca |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CN114729031A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CN114729031A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CN114729031A3</originalsourceid><addsrcrecordid>eNrjZHByzCvJ1M3PS87PqSzJTFYoyywqLVZIBAqmp-aB6aT8lMxUkFCKQm5qSUZ-SrFCfppCaXGqQklGalFqfhoPA2taYk5xKi-U5mZQdHMNcfbQTS3Ij08tLkhMTs1LLYl39jM0NDE3sjQwNnQ0JkYNAFXoMiU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Anti-oncolytic virus antigen antibodies and methods of use thereof</title><source>esp@cenet</source><creator>BERNARD, FRANU OIS ; CUMMINGS EMMA J ; ROUSSEAU JULIE MARIE ; LIN GUOXIAN ; BERGQVIST JAN PETER ; THUMASI-BOATENG KWAME ; GUO YINYU EUNICE ; NELSON BRAD ; SMACINSKI, JULIAN</creator><creatorcontrib>BERNARD, FRANU OIS ; CUMMINGS EMMA J ; ROUSSEAU JULIE MARIE ; LIN GUOXIAN ; BERGQVIST JAN PETER ; THUMASI-BOATENG KWAME ; GUO YINYU EUNICE ; NELSON BRAD ; SMACINSKI, JULIAN</creatorcontrib><description>Antibodies that specifically bind to a vaccinia virus (VV) A56 or B5 antigen are provided. Fusion proteins and conjugates comprising the antibodies are also provided. Pharmaceutical compositions and kits comprising the antibodies, fusion proteins and conjugates are also provided. Aspects of the disclosure further include methods of using the antibodies, fusion proteins, and conjugates, for example, for therapeutic purposes. In certain embodiments, methods are provided comprising administering to an individual having cancer an antibody, fusion protein or conjugate of the present disclosure wherein the individual comprises cancer cells infected with VV, such as cancer cells infected with VV. And wherein the antibody, fusion protein or conjugate is targeted to a VV antigen infected cancer cell expressed on the surface of the infected cancer cell. Aspects of the disclosure further include methods of targeting an antibody, fusion protein or conjugate that specifically binds to an oncolytic virus (OV) antigen to ca</description><language>chi ; eng</language><subject>CHEMISTRY ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220708&DB=EPODOC&CC=CN&NR=114729031A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25543,76293</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220708&DB=EPODOC&CC=CN&NR=114729031A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>BERNARD, FRANU OIS</creatorcontrib><creatorcontrib>CUMMINGS EMMA J</creatorcontrib><creatorcontrib>ROUSSEAU JULIE MARIE</creatorcontrib><creatorcontrib>LIN GUOXIAN</creatorcontrib><creatorcontrib>BERGQVIST JAN PETER</creatorcontrib><creatorcontrib>THUMASI-BOATENG KWAME</creatorcontrib><creatorcontrib>GUO YINYU EUNICE</creatorcontrib><creatorcontrib>NELSON BRAD</creatorcontrib><creatorcontrib>SMACINSKI, JULIAN</creatorcontrib><title>Anti-oncolytic virus antigen antibodies and methods of use thereof</title><description>Antibodies that specifically bind to a vaccinia virus (VV) A56 or B5 antigen are provided. Fusion proteins and conjugates comprising the antibodies are also provided. Pharmaceutical compositions and kits comprising the antibodies, fusion proteins and conjugates are also provided. Aspects of the disclosure further include methods of using the antibodies, fusion proteins, and conjugates, for example, for therapeutic purposes. In certain embodiments, methods are provided comprising administering to an individual having cancer an antibody, fusion protein or conjugate of the present disclosure wherein the individual comprises cancer cells infected with VV, such as cancer cells infected with VV. And wherein the antibody, fusion protein or conjugate is targeted to a VV antigen infected cancer cell expressed on the surface of the infected cancer cell. Aspects of the disclosure further include methods of targeting an antibody, fusion protein or conjugate that specifically binds to an oncolytic virus (OV) antigen to ca</description><subject>CHEMISTRY</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZHByzCvJ1M3PS87PqSzJTFYoyywqLVZIBAqmp-aB6aT8lMxUkFCKQm5qSUZ-SrFCfppCaXGqQklGalFqfhoPA2taYk5xKi-U5mZQdHMNcfbQTS3Ij08tLkhMTs1LLYl39jM0NDE3sjQwNnQ0JkYNAFXoMiU</recordid><startdate>20220708</startdate><enddate>20220708</enddate><creator>BERNARD, FRANU OIS</creator><creator>CUMMINGS EMMA J</creator><creator>ROUSSEAU JULIE MARIE</creator><creator>LIN GUOXIAN</creator><creator>BERGQVIST JAN PETER</creator><creator>THUMASI-BOATENG KWAME</creator><creator>GUO YINYU EUNICE</creator><creator>NELSON BRAD</creator><creator>SMACINSKI, JULIAN</creator><scope>EVB</scope></search><sort><creationdate>20220708</creationdate><title>Anti-oncolytic virus antigen antibodies and methods of use thereof</title><author>BERNARD, FRANU OIS ; CUMMINGS EMMA J ; ROUSSEAU JULIE MARIE ; LIN GUOXIAN ; BERGQVIST JAN PETER ; THUMASI-BOATENG KWAME ; GUO YINYU EUNICE ; NELSON BRAD ; SMACINSKI, JULIAN</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CN114729031A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng</language><creationdate>2022</creationdate><topic>CHEMISTRY</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><toplevel>online_resources</toplevel><creatorcontrib>BERNARD, FRANU OIS</creatorcontrib><creatorcontrib>CUMMINGS EMMA J</creatorcontrib><creatorcontrib>ROUSSEAU JULIE MARIE</creatorcontrib><creatorcontrib>LIN GUOXIAN</creatorcontrib><creatorcontrib>BERGQVIST JAN PETER</creatorcontrib><creatorcontrib>THUMASI-BOATENG KWAME</creatorcontrib><creatorcontrib>GUO YINYU EUNICE</creatorcontrib><creatorcontrib>NELSON BRAD</creatorcontrib><creatorcontrib>SMACINSKI, JULIAN</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>BERNARD, FRANU OIS</au><au>CUMMINGS EMMA J</au><au>ROUSSEAU JULIE MARIE</au><au>LIN GUOXIAN</au><au>BERGQVIST JAN PETER</au><au>THUMASI-BOATENG KWAME</au><au>GUO YINYU EUNICE</au><au>NELSON BRAD</au><au>SMACINSKI, JULIAN</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Anti-oncolytic virus antigen antibodies and methods of use thereof</title><date>2022-07-08</date><risdate>2022</risdate><abstract>Antibodies that specifically bind to a vaccinia virus (VV) A56 or B5 antigen are provided. Fusion proteins and conjugates comprising the antibodies are also provided. Pharmaceutical compositions and kits comprising the antibodies, fusion proteins and conjugates are also provided. Aspects of the disclosure further include methods of using the antibodies, fusion proteins, and conjugates, for example, for therapeutic purposes. In certain embodiments, methods are provided comprising administering to an individual having cancer an antibody, fusion protein or conjugate of the present disclosure wherein the individual comprises cancer cells infected with VV, such as cancer cells infected with VV. And wherein the antibody, fusion protein or conjugate is targeted to a VV antigen infected cancer cell expressed on the surface of the infected cancer cell. Aspects of the disclosure further include methods of targeting an antibody, fusion protein or conjugate that specifically binds to an oncolytic virus (OV) antigen to ca</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | chi ; eng |
| recordid | cdi_epo_espacenet_CN114729031A |
| source | esp@cenet |
| subjects | CHEMISTRY METALLURGY ORGANIC CHEMISTRY PEPTIDES |
| title | Anti-oncolytic virus antigen antibodies and methods of use thereof |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T22%3A50%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=BERNARD,%20FRANU%20OIS&rft.date=2022-07-08&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECN114729031A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |